Physician profile
David Kotlaba
NPI 1164512836
$3,489.35
in general payments reported to CMS, 2019-2025
28 companies · $779 in 2025
The $779 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $380 · 2020: $187 · 2021: $525 · 2022: $246 · 2023: $657 · 2024: $715 · 2025: $779.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,051 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,051.07 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $616.69 | 2020-2025 | Wainua, Farxiga, Brilinta |
| Novartis Pharmaceuticals Corporation | $403.79 | 2020-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $377.60 | 2019-2025 | Lifevest |
| Janssen Pharmaceuticals, INC | $348.64 | 2020-2024 | Xarelto |
| Vifor Pharma, INC. | $200.00 | 2021 | |
| Novo Nordisk INC | $195.08 | 2019-2025 | Ozempic, Wegovy |
| Amgen INC. | $164.74 | 2023-2025 | Repatha, Repatha |
| Pfizer INC. | $146.20 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $136.93 | 2019-2024 | Camzyos, Eliquis |
| Lexicon Pharmaceuticals, INC. | $133.50 | 2023-2024 | Inpefa |
| Esperion Therapeutics, INC. | $118.14 | 2021-2024 | Nexletol |
| Actelion Pharmaceuticals US, INC. | $99.99 | 2023 | Opsumit, Uptravi |
| Medtronic Vascular, INC. | $61.67 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $58.64 | 2019 | |
| Boston Scientific Corporation | $45.00 | 2019 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ge Healthcare | $44.48 | 2019 | |
| Kiniksa Pharmaceuticals International, Plc | $42.60 | 2024 | Arcalyst |
| Merck Sharp & Dohme LLC | $38.44 | 2022-2023 | Verquvo |
| Bayer Healthcare Pharmaceuticals INC. | $37.62 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.33 | 2024 | Jardiance |
| Medtronic, INC. | $33.18 | 2022 | |
| Cvrx, INC. | $27.89 | 2022 | |
| Inspire Medical Systems, INC. | $27.55 | 2025 | Inspire |
| Abbott Laboratories | $24.02 | 2024 | Cardiomems |
| Bardy Diagnostics, INC. | $20.00 | 2022 | |
| Bard Peripheral Vascular, INC. | $19.15 | 2024 | Venclose Maven Catheter |
| Alnylam Pharmaceuticals INC. | $16.98 | 2024 | Onpattro |
| Biocompatibles, INC. | $15.50 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Kotlaba listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.